NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Highly Specialised Technologies Evaluation Committee (HSTEC) meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 10 January 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Paul Arundel (Chair) Present for all items
2. Annett Blochberger Present for all items
3. Emtiyaz Chowdhury Present for all items
4. Sarah Davis Present for all items
5. Carrie Gardner Present for all items
6. Professor Jonathan Ives Items 1.1 to 5.1.3
7. Stuart Mealing Present for all items
8. Sara Payne Present for all items
9. Steve O’Brien Items 1.1 to 4.3.2
10. Giles Monnickendam Present for all items
11. Hugo Pedder Present for all items
12. Prithwiraj Das Present for all items
13. Michael Chambers Present for all items

NICE staff (key players) present

Emily Crowe, Associate Director Present for all items

Leena Issa, Project Manager Present for all items

Alan Moore, Health Technology Assessment Adviser Items 1.1 to 4.3.2

Sharlene Ting, Health Technology Assessment Analyst Items 1.1 to 4.3.2

Claire Hawksworth, Health Technology Assessment Adviser Items 5.1 to 5.2.2

Thomas Palmer, Health Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Tracey Jhita, BMJ Technology Assessment Group Items 1.1 to 4.2.1

Ben Farrar, BMJ Technology Assessment Group Items 1.1 to 4.2.1

Vicky Wakefield, BMJ Technology Assessment Group Item 5.1 to 5.1.3

Kate Ennis, BMJ Technology Assessment Group Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Neil Rabin, Consultant Haematologist and Chair of UK Myeloma Society, Clinical expert nominated by UK Myeloma Society Items 1.1 to 4.1.3

Items 5.1 to 5.1.3

Karthik Ramasamy, Associate Professor and Consultant Haematologist, Clinical expert nominated by UK Myeloma Society Items 1.1 to 4.1.3

Scott Purdon, Head of Patient Advocacy of Myeloma UK, Patient expert nominated by Myeloma UK Items 1.1 to 4.1.3 /

Items 5.1 to 5.1.3

Rosemary Dill, Patient expert nominated by Myeloma UK Items 1.1 to 4.1.3

Items 5.1 to 5.1.3

Peter Clark, CDF Clinical Lead, NHSE Present for all items

Ceri Bygrave, Consultant, Clinical expert nominated by GlaxoSmithKline

Items 5.1 to 5.1.3

Observers present

Sara Pickett, All Wales Therapeutics and Toxicology Centre Items 5.1 to 5.2.2

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Tina Garvey, Shehla Mohammed, Ed Wilson, Angharad Shambler and Anthony Williams.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 7 December 2023

### Evaluation of [selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]](https://www.nice.org.uk/guidance/indevelopment/gid-ta10646)

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Menarini Stemline.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10646).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Carrie Gardner (clinical), Jonathan Ives (lay), and Stuart Mealing (cost).
  2. Part 2a – Closed session (company representatives, patient and clinical experts and members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  3. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10646>.

### Evaluation of [selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments [ID6193]](https://www.nice.org.uk/guidance/awaiting-development/gid-ta11223)

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Menarini Stemline.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/awaiting-development/gid-ta11223).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Annett Blochberger (clinical), Jonathan Ives (lay) and Emtiyaz Chowdhury (cost).
  2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/awaiting-development/gid-ta11223>.

### Date of the next meeting

The next meeting of the Highly Specialised Technologies Evaluation Committee (HSTEC) will be held on Wednesday 14 February 2024 and will start promptly at 9:00.